retatrutide eli lilly phase 2 results Lilly's triple agonist, retatrutide, successful in two additional 3 obesity trials, delivering significant improvements in weight and A1C Drug retatrutide helps people lower

PlexusDx's Precision Peptide Genetic Test maps 14 metabolic and neurological pathways across 49 peptides to identify your individual predisposition to mood shifts on GLP-1 therapy

Strategic cycling alternates periods on medication (typically 3-6 months) with periods attempting lifestyle-only maintenance

Hair loss: diagnosis and treatment

A population-based study of 467 matched pairs of GLP-1 users and non-users with type 2 diabetes and liver cirrhosis found GLP-1 use associated with lower risks of death, cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and liver failure

Prioritizing nutrient-dense foods and moving your body more are important to improving your long-term health when taking a GLP-1